DOI: 10.1055/s-00000133

Gastroenterologie up2date


Hurwitz H, Fehrenbacher L, Cartwright T. et al.
Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluoruracil, leucovorin) as first line therapy in subjects with metastatic CRC. 
Proc Am Soc Clin Oncol 2003; 22: 3636-  

Download Bibliographical Data

Search in: